vs
Side-by-side financial comparison of Emergent BioSolutions Inc. (EBS) and InvenTrust Properties Corp. (IVT). Click either name above to swap in a different company.
Emergent BioSolutions Inc. is the larger business by last-quarter revenue ($148.7M vs $77.4M, roughly 1.9× InvenTrust Properties Corp.). InvenTrust Properties Corp. runs the higher net margin — 3.4% vs -36.7%, a 40.2% gap on every dollar of revenue. On growth, InvenTrust Properties Corp. posted the faster year-over-year revenue change (8.6% vs -23.6%). InvenTrust Properties Corp. produced more free cash flow last quarter ($110.9M vs $73.8M). Over the past eight quarters, InvenTrust Properties Corp.'s revenue compounded faster (7.6% CAGR vs -29.6%).
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
InvenTrust Properties Corp. is a real estate investment trust that invests in shopping malls. As of December 31, 2024, the company owned interests in 68 properties comprising 11.0 million square feet.
EBS vs IVT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.7M | $77.4M |
| Net Profit | $-54.6M | $2.7M |
| Gross Margin | 42.9% | — |
| Operating Margin | -18.8% | -11.0% |
| Net Margin | -36.7% | 3.4% |
| Revenue YoY | -23.6% | 8.6% |
| Net Profit YoY | -74.4% | -72.8% |
| EPS (diluted) | $-0.95 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.7M | $77.4M | ||
| Q3 25 | $231.1M | $74.5M | ||
| Q2 25 | $140.9M | $73.6M | ||
| Q1 25 | $222.2M | $73.8M | ||
| Q4 24 | $194.7M | $71.2M | ||
| Q3 24 | $293.8M | $68.5M | ||
| Q2 24 | $254.7M | $67.4M | ||
| Q1 24 | $300.4M | $66.8M |
| Q4 25 | $-54.6M | $2.7M | ||
| Q3 25 | $51.2M | $6.0M | ||
| Q2 25 | $-12.0M | $95.9M | ||
| Q1 25 | $68.0M | $6.8M | ||
| Q4 24 | $-31.3M | $9.8M | ||
| Q3 24 | $114.8M | $-539.0K | ||
| Q2 24 | $-283.1M | $1.5M | ||
| Q1 24 | $9.0M | $2.9M |
| Q4 25 | 42.9% | — | ||
| Q3 25 | 62.8% | — | ||
| Q2 25 | 52.5% | — | ||
| Q1 25 | 60.2% | — | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | -18.8% | — | ||
| Q1 24 | 49.2% | — |
| Q4 25 | -18.8% | -11.0% | ||
| Q3 25 | 33.1% | -9.8% | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 22.5% | -10.5% | ||
| Q4 24 | -4.9% | -3.6% | ||
| Q3 24 | 22.0% | -18.7% | ||
| Q2 24 | -79.9% | -13.6% | ||
| Q1 24 | 13.2% | -13.1% |
| Q4 25 | -36.7% | 3.4% | ||
| Q3 25 | 22.2% | 8.1% | ||
| Q2 25 | -8.5% | 130.4% | ||
| Q1 25 | 30.6% | 9.2% | ||
| Q4 24 | -16.1% | 13.8% | ||
| Q3 24 | 39.1% | -0.8% | ||
| Q2 24 | -111.2% | 2.2% | ||
| Q1 24 | 3.0% | 4.3% |
| Q4 25 | $-0.95 | $0.02 | ||
| Q3 25 | $0.91 | $0.08 | ||
| Q2 25 | $-0.22 | $1.23 | ||
| Q1 25 | $1.19 | $0.09 | ||
| Q4 24 | $-0.45 | $0.14 | ||
| Q3 24 | $2.06 | $-0.01 | ||
| Q2 24 | $-5.38 | $0.02 | ||
| Q1 24 | $0.17 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $205.4M | — |
| Total DebtLower is stronger | $589.7M | $825.9M |
| Stockholders' EquityBook value | $522.6M | $1.8B |
| Total Assets | $1.3B | $2.8B |
| Debt / EquityLower = less leverage | 1.13× | 0.46× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $205.4M | — | ||
| Q3 25 | $245.5M | — | ||
| Q2 25 | $267.3M | — | ||
| Q1 25 | $149.1M | — | ||
| Q4 24 | $99.5M | — | ||
| Q3 24 | $149.9M | — | ||
| Q2 24 | $69.7M | — | ||
| Q1 24 | $78.5M | — |
| Q4 25 | $589.7M | $825.9M | ||
| Q3 25 | $693.1M | $764.6M | ||
| Q2 25 | $700.0M | $746.3M | ||
| Q1 25 | $700.0M | $740.7M | ||
| Q4 24 | $700.0M | $740.4M | ||
| Q3 24 | $700.8M | $740.1M | ||
| Q2 24 | $863.8M | $812.2M | ||
| Q1 24 | $909.2M | $827.5M |
| Q4 25 | $522.6M | $1.8B | ||
| Q3 25 | $582.5M | $1.8B | ||
| Q2 25 | $536.2M | $1.8B | ||
| Q1 25 | $552.7M | $1.7B | ||
| Q4 24 | $482.8M | $1.8B | ||
| Q3 24 | $508.4M | $1.8B | ||
| Q2 24 | $386.3M | $1.5B | ||
| Q1 24 | $663.9M | $1.5B |
| Q4 25 | $1.3B | $2.8B | ||
| Q3 25 | $1.5B | $2.7B | ||
| Q2 25 | $1.4B | $2.7B | ||
| Q1 25 | $1.4B | $2.6B | ||
| Q4 24 | $1.4B | $2.6B | ||
| Q3 24 | $1.5B | $2.6B | ||
| Q2 24 | $1.5B | $2.5B | ||
| Q1 24 | $1.8B | $2.5B |
| Q4 25 | 1.13× | 0.46× | ||
| Q3 25 | 1.19× | 0.42× | ||
| Q2 25 | 1.31× | 0.41× | ||
| Q1 25 | 1.27× | 0.42× | ||
| Q4 24 | 1.45× | 0.42× | ||
| Q3 24 | 1.38× | 0.42× | ||
| Q2 24 | 2.24× | 0.53× | ||
| Q1 24 | 1.37× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $77.7M | $155.4M |
| Free Cash FlowOCF − Capex | $73.8M | $110.9M |
| FCF MarginFCF / Revenue | 49.6% | 143.3% |
| Capex IntensityCapex / Revenue | 2.6% | 57.5% |
| Cash ConversionOCF / Net Profit | — | 58.41× |
| TTM Free Cash FlowTrailing 4 quarters | $156.8M | $193.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.7M | $155.4M | ||
| Q3 25 | $-2.3M | $43.8M | ||
| Q2 25 | $106.4M | $48.7M | ||
| Q1 25 | $-11.2M | $20.2M | ||
| Q4 24 | $-79.9M | $136.9M | ||
| Q3 24 | $153.7M | $38.4M | ||
| Q2 24 | $47.5M | $46.7M | ||
| Q1 24 | $-62.6M | $14.8M |
| Q4 25 | $73.8M | $110.9M | ||
| Q3 25 | $-5.7M | $31.4M | ||
| Q2 25 | $103.5M | $38.0M | ||
| Q1 25 | $-14.8M | $12.8M | ||
| Q4 24 | $-81.6M | $100.8M | ||
| Q3 24 | $147.9M | $29.3M | ||
| Q2 24 | $42.9M | $37.2M | ||
| Q1 24 | $-73.4M | $7.7M |
| Q4 25 | 49.6% | 143.3% | ||
| Q3 25 | -2.5% | 42.2% | ||
| Q2 25 | 73.5% | 51.6% | ||
| Q1 25 | -6.7% | 17.4% | ||
| Q4 24 | -41.9% | 141.5% | ||
| Q3 24 | 50.3% | 42.8% | ||
| Q2 24 | 16.8% | 55.2% | ||
| Q1 24 | -24.4% | 11.5% |
| Q4 25 | 2.6% | 57.5% | ||
| Q3 25 | 1.5% | 16.7% | ||
| Q2 25 | 2.1% | 14.6% | ||
| Q1 25 | 1.6% | 10.0% | ||
| Q4 24 | 0.9% | 50.7% | ||
| Q3 24 | 2.0% | 13.3% | ||
| Q2 24 | 1.8% | 14.0% | ||
| Q1 24 | 3.6% | 10.6% |
| Q4 25 | — | 58.41× | ||
| Q3 25 | -0.04× | 7.27× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | -0.16× | 2.97× | ||
| Q4 24 | — | 13.97× | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | — | 31.15× | ||
| Q1 24 | -6.96× | 5.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
IVT
Segment breakdown not available.
